StageZero Life Sciences Announces Results of Annual and Special Meeting

Biotech & MedTech

August 18, 2020 (Source) — StageZero Life Sciences, Ltd (TSX:SZLS) (“StageZero” or the “Company”) is pleased to report that shareholders voted in favour of all items of business, including the election of all nominee directors listed in the Company’s management information circular dated June 29, 2020 (the “Circular”), at its annual and special meeting of shareholders held on August 17, 2020 (the “Meeting”).

The results of the vote for the election of directors are set out below:


Votes For

Votes Withheld

James Howard-Tripp



Rory Riggs



Harry Glorikian



Garth MacCrae



In addition to the election of directors, shareholders voted in favour of the following matters:


Votes For

Votes Withheld

Appointment of BDO Canada LLP as auditors of the Company;



Votes For

Votes Against

Approval of a consolidation of the Company’s common shares (approved by ballot)



More specific details of the matters approved at the Meeting are set forth in the Circular and posted on the System for Electronic Data Analysis and Retrieval (SEDAR) at Voting results are released in accordance with Toronto Stock Exchange (“TSX”) requirements.

About StageZero Life Sciences, Ltd.
StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of Cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (live virus) and blood test analysis (Antibody testing). Our full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups. As we provide COVID-19 testing during this Pandemic, we continue making progress with our mission to eradicate late stage cancers through early detection. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer.

Forward-Looking Statements
This press release contains forward-looking statements identified by words such as “expects”, “will” and similar expressions, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company’s actual events to differ materially from those projected herein. Investors should consult the Company’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.